BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus

(Corrects headline and bullets to show company gets approval for clinical trial to test Favipiravir for pneumonia caused by novel coronavirus)

Feb 17 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd :

* RECEIVES APPROVAL TO MANUFACTURE FAVIPIRAVIR FOR NEW AND RECURRING INFLUENZA IN ADULTS

* SAYS IT RECEIVES APPROVAL TO START CLINICAL TRIALS FOR USE OF FAVIPIRAVIR TO TREAT PNEUMONIA CAUSED BY NEW CORONAVIRUS Source text in Chinese: https://bit.ly/2SKKE3S Further company coverage: (Reporting by Hong Kong newsroom; Editing by Tom Hogue)

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.